Poplar Therapeutics
Poplar Therapeutics47About
What does Poplar Therapeutics do?
Poplar Therapeutics is a biotechnology company focused on developing novel therapies for atopic conditions. Their lead program, PHB-050, is a new class of anti-IgE therapy designed to address a range of allergic diseases.
What is Poplar Therapeutics's revenue?
StartupHub estimates Poplar Therapeutics's annual revenue at $2.1M (range $1.2M to $5.4M, 68% confidence), based on comparable companies in the sector.
What is Poplar Therapeutics's valuation?
StartupHub estimates Poplar Therapeutics's effective valuation at $193.1M (range $125.0M to $300.0M, 22% confidence), based on comparable companies in the sector.
How much funding has Poplar Therapeutics raised?
Poplar Therapeutics has raised a total of $50M in funding. The most recent round on record is Series A.
Where is Poplar Therapeutics headquartered?
Poplar Therapeutics is headquartered in Boston, Massachusetts, USA.
When was Poplar Therapeutics founded?
Poplar Therapeutics was founded in 2021.
What industry does Poplar Therapeutics operate in?
Poplar Therapeutics operates in Biotechnology, Pharmaceuticals, HealthTech, Biotech, Drug Discovery, Clinical Trials.
How many employees does Poplar Therapeutics have?
Poplar Therapeutics has approximately 15 people on record.
No comments yet. Be the first to share your take.